Literature DB >> 27064430

A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy.

Diana Abbott1, Nicholas E Johnson2, Lisa A Cannon-Albright3,4.   

Abstract

INTRODUCTION: The risk of cancer in patients diagnosed with myotonic dystrophy (DM) is reported for the homogeneous Utah population.
METHODS: Clinical data accessed from the largest Utah healthcare providers have been record-linked to the Utah Population Database, a population-based resource also linked to the Utah Cancer Registry. Relative risks were estimated for 36 cancers of different types in 281 DM patients.
RESULTS: Testicular cancer (relative risk [RR] = 10.74; 95% confidence interval [CI], 1.91-38.79), endometrial cancer (RR = 6.98; 95% CI, 1.24-25.22), and non-Hodgkin lymphoma (RR = 4.25; 95% CI, 1.16-12.43) were all observed at significant excess in DM patients.
CONCLUSIONS: This study confirms an overall increased risk of cancer in DM. Individuals diagnosed with DM might benefit from risk counseling. Muscle Nerve 54: 783-785, 2016.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  UPDB; cancer; myotonic dystrophy; neuromuscular disease; relative risk

Mesh:

Year:  2016        PMID: 27064430      PMCID: PMC5824717          DOI: 10.1002/mus.25145

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  15 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  Differences in CTG triplet repeat expansions in an ovarian cancer and cyst from a patient with myotonic dystrophy.

Authors:  M Kinoshita; A Igarashi; T Komori; H Tamura; M Hayashi; K Kinoshita; T Deguchi; K Hirose
Journal:  Muscle Nerve       Date:  1997-05       Impact factor: 3.217

3.  CTG triplet repeat expansion in a laryngeal carcinoma from a patient with myotonic dystrophy.

Authors:  R Osanai; M Kinoshita; K Hirose; T Homma; I Kawabata
Journal:  Muscle Nerve       Date:  2000-05       Impact factor: 3.217

4.  Dysplastic nevi, cutaneous melanoma, and other skin neoplasms in patients with myotonic dystrophy type 1: a cross-sectional study.

Authors:  Anna Zampetti; Gabriella Silvestri; Simona Manco; Katy Khamis; Marcella Masciullo; Maria Laura Ester Bianchi; Antonello Damiani; Massimo Santoro; Dennis Linder; Anthony Bewley; Claudio Feliciani
Journal:  J Am Acad Dermatol       Date:  2014-11-05       Impact factor: 11.527

5.  Increased cancer risks in myotonic dystrophy.

Authors:  Aung Ko Win; Promilla G Perattur; Jose S Pulido; Christine M Pulido; Noralane M Lindor
Journal:  Mayo Clin Proc       Date:  2012-01-10       Impact factor: 7.616

6.  [Increasing risk of tumors in myotonic dystrophy type 1].

Authors:  Shirine Mohamed; Lelia Pruna; Pierre Kaminsky
Journal:  Presse Med       Date:  2013-03-07       Impact factor: 1.228

Review 7.  Hypothesis: neoplasms in myotonic dystrophy.

Authors:  Christine M Mueller; James E Hilbert; William Martens; Charles A Thornton; Richard T Moxley; Mark H Greene
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

8.  Risk of cancer in relatives of patients with myotonic dystrophy: a population-based cohort study.

Authors:  M Lund; L J Diaz; S Gørtz; B Feenstra; M Duno; I Juncker; H Eiberg; J Vissing; J Wohlfahrt; M Melbye
Journal:  Eur J Neurol       Date:  2014-05-17       Impact factor: 6.089

9.  A comprehensive survey of cancer risks in extended families.

Authors:  Craig C Teerlink; Frederick S Albright; Lauro Lins; Lisa A Cannon-Albright
Journal:  Genet Med       Date:  2012-01       Impact factor: 8.822

10.  Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis.

Authors:  Shahinaz M Gadalla; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Magnus Björkholm; James E Hilbert; Richard T Moxley; Ola Landgren; Mark H Greene
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more
  10 in total

1.  Cancer phenotype in myotonic dystrophy patients: Results from a meta-analysis.

Authors:  Jose I Emparanza; Adolfo López de Munain; Mark H Greene; Ander Matheu; Roberto Fernández-Torrón; Shahinaz M Gadalla
Journal:  Muscle Nerve       Date:  2018-10       Impact factor: 3.217

2.  Benign and malignant tumors in the UK myotonic dystrophy patient registry.

Authors:  Rotana Alsaggaf; Youjin Wang; Chiara Marini-Bettolo; Libby Wood; Nikoletta Nikolenko; Hanns Lochmüller; Mark H Greene; Shahinaz M Gadalla
Journal:  Muscle Nerve       Date:  2017-07-24       Impact factor: 3.217

3.  Uveal Melanoma Associated With Myotonic Dystrophy: A Report of 6 Cases.

Authors:  Lauren A Dalvin; Carol L Shields; Jose S Pulido; Kareem Sioufi; Victoria Cohen; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2018-05-01       Impact factor: 7.389

4.  Survival patterns and cancer determinants in families with myotonic dystrophy type 1.

Authors:  A F Best; J E Hilbert; L Wood; W B Martens; N Nikolenko; C Marini-Bettolo; H Lochmüller; P S Rosenberg; R T Moxley; M H Greene; S M Gadalla
Journal:  Eur J Neurol       Date:  2018-09-16       Impact factor: 6.089

5.  Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity.

Authors:  Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla
Journal:  JNCI Cancer Spectr       Date:  2018-12-10

Review 6.  The Duchenne muscular dystrophy gene and cancer.

Authors:  Leanne Jones; Michael Naidoo; Lee R Machado; Karen Anthony
Journal:  Cell Oncol (Dordr)       Date:  2020-11-14       Impact factor: 6.730

7.  Benign tumors in myotonic dystrophy type I target disease-related cancer sites.

Authors:  Rotana Alsaggaf; Diane Marie M St George; Min Zhan; Ruth M Pfeiffer; Youjin Wang; Lesley A Anderson; Zhiwei Liu; Jill Koshiol; Andrew J Bauer; Kathryn R Wagner; Mark H Greene; Sania Amr; Shahinaz M Gadalla
Journal:  Ann Clin Transl Neurol       Date:  2019-07-26       Impact factor: 4.511

8.  Diabetes, metformin and cancer risk in myotonic dystrophy type I.

Authors:  Rotana Alsaggaf; Ruth M Pfeiffer; Youjin Wang; Diane Marie M St George; Min Zhan; Kathryn R Wagner; Sania Amr; Mark H Greene; Shahinaz M Gadalla
Journal:  Int J Cancer       Date:  2019-12-19       Impact factor: 7.316

9.  Mutation analysis of multiple pilomatricomas in a patient with myotonic dystrophy type 1 suggests a DM1-associated hypermutation phenotype.

Authors:  Albert Rübben; Renate Ursula Wahl; Thomas Eggermann; Edgar Dahl; Nadina Ortiz-Brüchle; Claudio Cacchi
Journal:  PLoS One       Date:  2020-03-10       Impact factor: 3.240

Review 10.  Targeting Myotonic Dystrophy Type 1 with Metformin.

Authors:  Mikel García-Puga; Ander Saenz-Antoñanzas; Ander Matheu; Adolfo López de Munain
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.